Beta Bionics (NASDAQ:BBNX) CFO Sells $311,773.68 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 15,018 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $20.76, for a total transaction of $311,773.68. Following the sale, the chief financial officer owned 44,041 shares in the company, valued at $914,291.16. This represents a 25.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Stephen Feider also recently made the following trade(s):

• On Friday, September 5th, Stephen Feider sold 100 shares of Beta Bionics stock. The shares were sold at an average price of $21.00, for a total transaction of $2,100.00.
• On Tuesday, September 2nd, Stephen Feider sold 1,462 shares of Beta Bionics stock. The stock was sold at an average price of $18.86, for a total transaction of $27,573.32.
• On Friday, August 22nd, Stephen Feider sold 4,413 shares of Beta Bionics stock. The stock was sold at an average price of $17.01, for a total transaction of $75,065.13.
• On Tuesday, August 19th, Stephen Feider sold 5,587 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total transaction of $95,146.61.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $22.26 on Friday. Beta Bionics, Inc. has a 1 year low of $8.89 and a 1 year high of $26.66. The firm has a 50-day simple moving average of $19.21 and a two-hundred day simple moving average of $15.78.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.12. The firm had revenue of $23.24 million during the quarter, compared to the consensus estimate of $19.73 million. Beta Bionics has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio bought a new position in shares of Beta Bionics during the first quarter valued at approximately $29,000. CWM LLC bought a new position in shares of Beta Bionics during the second quarter valued at approximately $58,000. Legal & General Group Plc boosted its stake in shares of Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after purchasing an additional 2,639 shares in the last quarter. Corebridge Financial Inc. bought a new position in shares of Beta Bionics during the first quarter valued at approximately $79,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Beta Bionics during the first quarter valued at approximately $95,000.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Lake Street Capital assumed coverage on shares of Beta Bionics in a research note on Thursday, June 12th. They issued a “buy” rating and a $30.00 price objective for the company. The Goldman Sachs Group set a $26.00 price objective on shares of Beta Bionics and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Beta Bionics in a research report on Saturday, September 27th. Robert W. Baird set a $17.00 target price on shares of Beta Bionics and gave the stock a “neutral” rating in a research report on Wednesday, July 30th. Finally, Truist Financial raised their target price on shares of Beta Bionics from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and an average price target of $24.44.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.